Company Received Direction From FDA for Study -- Will Focus Solely on the Furtherance of the Migraine Medicine to Bring to Market
SUN VALLEY, CA - (NewMediaWire) - January 21, 2016 - MultiCorp International, Inc. (OTC PINK: MCIC) has received a report from the U.S. Food and Drug Administration that gives the company specific guidelines in creating a 4 arm study to administer the patented migraine medicine in an emergency room setting.
The company released the following statement: "The company has received a detailed response to the Pre-IND submission sent to the U.S. Food and Drug Administration for the further development of the patented migraine medicine the company has ownership in. The FDA has responded in supplying the company with a clear roadmap to develop a 4 arm study wherein the medicine will be dispensed in an emergency room setting for patients that enter the ER for migraine relief. This study will give the company feedback on the efficacy of the drug as compared to other medications currently being dispensed to relieve migraines. This study significantly will speed up the process to bring the product to market."
The company also stated it is suspending all other areas of business to focus 100% on the further development of the medicine. As the migraine industry in the U.S. is currently in excess of $800 Million per year, the company feels that this medicine could capture a 10-15% market share which would place a value of the medicine at $80-$120 Million.
About MultiCorp International, Inc.
MultiCorp International, Inc. has committed itself to the further development of the patented migraine medicine the company owns a significant percentage of. The company has received information from the U.S. Food and Drug Administration that provides the company with a clear path to further the development of the drug to bring to market. The company is currently looking to partner with a pharmaceutical company that can assist the company in bringing the migraine medicine to market. For further information please contact them at email@example.com
This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets.
The news, reports, views and opinions of authors (or source) expressed are their own and do not necessarily represent the views of CRWE World.